These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 39118)

  • 21. Brain receptors for dopamine and neuroleptics.
    Seeman P; Titeler M; Tedesco J; Weinreich P; Sinclair D
    Adv Biochem Psychopharmacol; 1978; 19():167-76. PubMed ID: 29446
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacological vs. clinical physiognomy of neuroleptics, with special reference to their sedative and antipsychotic effects.
    Nielsen IM
    Acta Psychiatr Belg; 1974 Sep; 74(5):473-84. PubMed ID: 4471027
    [No Abstract]   [Full Text] [Related]  

  • 23. Can neuroleptics influence the function of the brain hemispheres asymmetrically?
    Fritze J
    Neuropharmacology; 1984 Jan; 23(1):79-82. PubMed ID: 6144067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of leu-enkephalin binding by neuroleptics.
    Somoza E; Bazán E; Galindo A
    Neuropsychobiology; 1982; 8(6):297-303. PubMed ID: 6131391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative studies on flupenthixol and flupenthixol decanoate in amimal and man.
    Jorgensen A; Gottfries CG
    Therapie; 1973; 28(3):459-73. PubMed ID: 4771901
    [No Abstract]   [Full Text] [Related]  

  • 26. [Differences in the efficiency of their interaction with membrane receptors of the dialkylaminoalkyl and dialkylaminoacyl derivatives of phenothiazine].
    Savel'eva MV; Ratner EI; Baldenko GN; Kaverina NV
    Biull Eksp Biol Med; 1990 Mar; 109(3):266-8. PubMed ID: 1973058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism.
    Miller RJ; Hiley CR
    Nature; 1974 Apr; 248(449):596-7. PubMed ID: 4150951
    [No Abstract]   [Full Text] [Related]  

  • 28. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects.
    Svartengren J; Pettersson E; Björk A
    Biol Psychiatry; 1997 Aug; 42(4):247-59. PubMed ID: 9270901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptational phenomena in neuroleptic treatment.
    Nielsen IM; Christensen AV; Hyttel J
    Adv Biochem Psychopharmacol; 1978; 19():267-74. PubMed ID: 29449
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of a single dose of some long-acting neuroleptics on the estrus cycle and the mammary gland of the rat].
    Lanza JP; Goude F; Lanza M
    C R Seances Soc Biol Fil; 1979; 173(4):797-806. PubMed ID: 43191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.
    Tam SW; Cook L
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5618-21. PubMed ID: 6147851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The main clinical classifications of neuroleptics.
    Collard J
    Acta Psychiatr Belg; 1974 Sep; 74(5):447-61. PubMed ID: 4157188
    [No Abstract]   [Full Text] [Related]  

  • 33. Social isolation in the young rat: neurochemical effects of treatment with a long-acting neuroleptic, alpha-flupenthixol decanoate [proceedings].
    Morinan A; Leonard BE
    Br J Pharmacol; 1978 Nov; 64(3):379P-380P. PubMed ID: 719238
    [No Abstract]   [Full Text] [Related]  

  • 34. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
    Spano PF; Memo M; Govoni S; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
    [No Abstract]   [Full Text] [Related]  

  • 35. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding.
    Leysen JE; Gommeren W; Laduron PM
    Biochem Pharmacol; 1978 Feb; 27(3):307-16. PubMed ID: 23126
    [No Abstract]   [Full Text] [Related]  

  • 36. Relative potency of some neuroleptics as antagonists at dopamine-receptors in vivo compared with their reported ability to displace haloperidol binding in vitro [proceedings].
    Cox B; Ennis C; Foote G
    Br J Pharmacol; 1980 Jan; 68(1):172P. PubMed ID: 6101975
    [No Abstract]   [Full Text] [Related]  

  • 37. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.
    Ereshefsky L; Saklad SR; Jann MW; Davis CM; Richards A; Seidel DR
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):50-9. PubMed ID: 6143748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
    Marshall AM; Mishra RK
    Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
    [No Abstract]   [Full Text] [Related]  

  • 39. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics.
    Kendler KS; Bracha HS; Davis KL
    Eur J Pharmacol; 1982 Apr; 79(3-4):217-23. PubMed ID: 6124428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Piracetam interactions with neuroleptics in psychopharmacological tests.
    Bourin M; Poisson L; Larousse C
    Neuropsychobiology; 1986; 16(2-3):93-6. PubMed ID: 2884593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.